IP Library Granted Patent US 12,403,091
Granted Patent B2
US 12,403,091 · App. 18/205,995 · Granted Sep 2, 2025

Delivery system

Inventor: Thomas Hnat (Santee, CA)
Assignee: SMARTECH TOPICAL, INC.
A61K9/06A61K9/0014A61K31/167A61K31/192A61K31/196A61K31/216A61K31/245A61K31/352A61K31/385A61K31/522A61K31/714A61K45/06A61K47/10A61K47/14A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,403,091
App. No.
18/205,995
Granted
Sep 2, 2025
Kind
B2
Abstract

In accordance with the present disclosure, there are provided formulations comprising: (a) at least one active agent; (b) an oil, and optionally a thickener therefor; (c) an organic solvent, and a thickener therefor; and (d) an oil and/or solvent soluble skin penetration enhancer; wherein: said formulation comprises <10 wt % water; and said formulation optionally forms a thixotropic thinning gel. Also provided are gels comprising oil and organic solvent, methods for preparing same and methods for the topical delivery of an active agent to a subject in need thereof.

Claims (27)

1. A method for the topical delivery of diclofenac to a subject in need thereof, comprising:

topically applying a non-aqueous transparent gel formulation to the subject, the non-aqueous transparent gel formulation comprising

(a) diclofenac;

(b) oleic acid;

(c) at least one organic solvent selected from the group consisting of dimethyl isosorbide, dimethyl formamide, ethanol, ethyl acetate, 1,2-propanediol, 1,3-propanediol, and glycerin;

(d) dimethylsulfoxide; and

(e) hydroxypropyl cellulose.

2. The method of claim 1 , wherein the non-aqueous transparent gel formulation further comprises 2.0 wt % to 5.0 wt % of at least one compound selected from the group consisting of Dibutyl Lauroyl Glutamide, Dibutyl Ethylhexanol Glutamide, Poloxamer 124, Poloxamer 188, Poloxamer 237, Poloxamer 337, Poloxamer 408, and Polyamide 8.

3. The method of claim 1 , wherein component (c) of the non-aqueous transparent gel formulation comprises ethanol and the combined concentration of dimethylsulfoxide and component (c) in the formulation is 30 wt % to 60 wt %.

4. The method of claim 2 , wherein component (c) of the non-aqueous transparent gel formulation comprises ethanol and the combined concentration of dimethylsulfoxide and component (c) in the formulation is 30 wt % to 60 wt %.

5. The method of claim 1 , wherein the at least one organic solvent comprises 1,2-propanediol.

6. The method of claim 2 , wherein the at least one organic solvent comprises 1,2-propanediol.

7. The method of claim 1 , wherein component (a) of the non-aqueous transparent gel formulation comprises 1-10 wt % diclofenac or a salt thereof.

8. The method of claim 2 , wherein component (a) of the non-aqueous transparent gel formulation comprises 1-10 wt % diclofenac or a salt thereof.

9. The method of claim 3 , wherein component (a) of the non-aqueous transparent gel formulation comprises 1-10 wt % diclofenac or a salt thereof.

10. The method of claim 4 , wherein component (a) of the non-aqueous transparent gel formulation comprises 1-10 wt % diclofenac or a salt thereof.

11. The method of claim 5 , wherein component (a) of the non-aqueous transparent gel formulation comprises 1-10 wt % diclofenac or a salt thereof.

12. The method of claim 6 , wherein component (a) of the non-aqueous transparent gel formulation comprises 1-10 wt % diclofenac or a salt thereof.

13. A method for the topical delivery of diclofenac to a subject in need thereof, comprising:

topically applying a non-aqueous transparent gel formulation to the subject, the non-aqueous transparent gel formulation comprising

(a) diclofenac or a salt thereof;

(b) oleic acid;

(c) ethanol

(d) hydroxypropyl cellulose;

(e) propylene glycol; and

(f) dimethylsulfoxide,

wherein said non-aqueous transparent gel formulation comprises 2-5 wt % hydroxypropyl cellulose, 1-10 wt % diclofenac or a salt thereof, and a combined concentration of dimethylsulfoxide and ethanol of 30-60 wt %.

Continuity (3)
Division 16087989
Provisional Application 62316064 · Mar 31, 2016
Related Publication 20230310318A1 · Oct 5, 2023
References Cited (28)
US 7622138B2 · Murthy · 2009 [cited by applicant]
US 8980290B2 · Carrara · 2015 [cited by examiner]
US 9012402B1 · Blanchard · 2015 [cited by applicant]
US 10702469B2 · Patel · 2020 [cited by applicant]
US 11666531B2 · Hnat · 2023 [cited by applicant]
US 20080319092A1 · Singh · 2008 [cited by examiner]
US 20100120918A1 · Patel · 2010 [cited by examiner]
US 20110300083A1 · Yontz et al. · 2011 [cited by applicant]
US 20120213842A1 · Birbara · 2012 [cited by applicant]
US 20120244090A1 · Martinetti et al. · 2012 [cited by applicant]
US 20140088195A1 · Buyuktimkin · 2014 [cited by examiner]
US 20160022603A1 · Spakevicius et al. · 2016 [cited by applicant]
US 20160101077A1 · Bannister et al. · 2016 [cited by applicant]
US 20160213784A1 · Kisak et al. · 2016 [cited by applicant]
US 20180250242A1 · Spakevicius · 2018 [cited by examiner]
CN 102652730B · 2014 [cited by applicant]
JP S63225312A2 · 1988 [cited by applicant]
JP H04124134A2 · 1992 [cited by applicant]
JP 2006265153A2 · 2006 [cited by applicant]
JP 2014513132A2 · 2014 [cited by applicant]
JP 2015164950A2 · 2015 [cited by applicant]
JP 2016502530A2 · 2016 [cited by applicant]
WO 2009047785A2 · 2009 [cited by applicant]
WO 2013088375A1 · 2013 [cited by applicant]
WO 2017173269A1 · 2017 [cited by applicant]
Office Action issued by the JPO in Japanese Patent Application No. 2019-502529 dated Feb. 24, 2021—incl Engl lang transl (20 pages total). [cited by applicant]
International Search Report and Written Opinion mailed Jun. 22, 2017, for International Application No. PCT/US2017/025373 (6 pages). [cited by applicant]
The Extended European Search Report issued in EP 17776775 dated Nov. 11, 2019 (7 pages). [cited by applicant]